In:
Journal of Biomedical Nanotechnology, American Scientific Publishers, Vol. 19, No. 5 ( 2023-05-01), p. 872-880
Abstract:
This study aimed to investigate the therapeutic potential of dasatinib, an FDA-approved drug for chronic myeloid leukemia, in sepsis-induced acute lung injury (ALI). In the in vitro part of the study, RAW 264.7 macrophages were stimulated with lipopolysaccharide (LPS), and the
anti-inflammatory effects of dasatinib were assessed by measuring pro-inflammatory mediators and cytokines. In the in vivo part, ALI was induced in mice through intraperitoneal LPS injection. The researchers investigated alveolar-capillary permeability, the inflammatory response, and
the therapeutic efficacy of dasatinib in ALI. Dasatinib administration was found to attenuate inflammation by inhibiting the m TOR pathway. In the in vivo experiments, dasatinib reduced the levels of pro-inflammatory cytokines and chemokines in bronchoalveolar lavage fluid (BALF). It
also decreased lung tissue permeability, as evidenced by a lower amount of Evans blue dye detected after ALI. Furthermore, dasatinib alleviated lung histological damage and reduced the lung injury grade, demonstrating its protective role in ALI. By inhibiting the mTOR pathway in macrophages, dasatinib exhibited a protective and anti-inflammatory effect on ALI. It reduced the intrapulmonary inflammatory response, prevented capillary disruption, and inhibited the accumulation of inflammatory cells. These findings suggest that dasatinib holds promise as a potential treatment option
for protecting lung tissue in ALI.
Type of Medium:
Online Resource
ISSN:
1550-7033
DOI:
10.1166/jbn.2023.3610
Language:
English
Publisher:
American Scientific Publishers
Publication Date:
2023
Permalink
